Abstract

Reverse Transcription quantitative Polymerase Chain Reaction (RT-qPCR) is a method of choice for quantifying micro RNAs (miRNAs). Typically, RT-qPCR data are normalized to reference genes. While miRNAs are used for diagnosing and subtyping breast cancer, various studies show their deregulation in this condition, thus, undermining miRNAs’ utility as a reference. This review examines the expression pattern of miR-16 and suggests normalization approaches for breast cancer. We analyzed the data from selected peer-reviewed studies to calculate the standardized mean difference (SMD) with subsequent Chi-square testing and identified the difference in miR-16 expression between breast cancer patients and healthy controls. With a negative SMD value of ‒0.56 and Chi-square of 62.62 (p-value = 0.05), the deregulation of miR-16 in breast cancer was confirmed. High variance in the stability value (SV) of miR-16 expression levels confirmed its inappropriateness as a control gene in breast cancer. The combination of miR-16 and miR-425 was confirmed as an accurate endogenous control.

中文翻译：

---

miRNA-16 作为乳腺癌研究的内部对照：系统评价和 Meta 分析

摘要

逆转录定量聚合酶链反应 (RT-qPCR) 是定量微 RNA (miRNA) 的首选方法。通常，RT-qPCR 数据被标准化为参考基因。虽然 miRNA 用于诊断和分型乳腺癌，但各种研究表明它们在这种情况下会失调，因此削弱了 miRNA 作为参考的效用。本综述检查了 miR-16 的表达模式，并提出了乳腺癌的标准化方法。我们分析了来自选定同行评审研究的数据，以通过随后的卡方检验计算标准化平均差 (SMD)，并确定乳腺癌患者和健康对照之间 miR-16 表达的差异。负 SMD 值为 ‒0.56，卡方值为 62.62 ( p-值 = 0.05)，证实了乳腺癌中 miR-16 的失调。miR-16 表达水平的稳定性值 (SV) 的高方差证实其不适合作为乳腺癌中的对照基因。miR-16 和 miR-425 的组合被证实为准确的内源性对照。